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Background: An increasing number of people on antiretroviral therapy (ART) in sub-Saharan Africa has led to
declines in HIV related morbidity and mortality. However, virologic failure (VF) and acquired drug resistance (ADR)
may negatively affect these gains. This study describes the prevalence and correlates of HIV-1 VF and ADR among
first-line ART experienced adults at a rural HIV clinic in Coastal Kenya.
Methods: HIV-infected adults on first-line ART for ≥6 months were cross-sectionally recruited between November
2008 and March 2011. The primary outcome was VF, defined as a one-off plasma viral load of ≥400 copies/ml. The
secondary outcome was ADR, defined as the presence of resistance associated mutations. Logistic regression and
Fishers exact test were used to describe correlates of VF and ADR respectively.
Results: Of the 232 eligible participants on ART over a median duration of 13.9 months, 57 (24.6% [95% CI:
19.2 – 30.6]) had VF. Fifty-five viraemic samples were successfully amplified and sequenced. Of these, 29
(52.7% [95% CI: 38.8 – 66.3]) had at least one ADR, with 25 samples having dual-class resistance mutations. The
most prevalent ADR mutations were the M184V (n = 24), K103N/S (n = 14) and Y181C/Y/I/V (n = 8). Twenty-six of
the 55 successfully amplified viraemic samples (47.3%) did not have any detectable resistance mutation. Younger
age (15–34 vs. ≥35 years: adjusted odd ratios [95% CI], p-value: 0.3 [0.1–0.6], p = 0.002) and unsatisfactory
adherence (<95% vs. ≥95%: 3.0 [1.5–6.5], p = 0.003) were strong correlates of VF. Younger age, unsatisfactory
adherence and high viral load were also strong correlates of ADR.
Conclusions: High levels of VF and ADR were observed in younger patients and those with unsatisfactory
adherence. Youth-friendly ART initiatives and strengthened adherence support should be prioritized in this Coastal
Kenyan setting. To prevent unnecessary/premature switches, targeted HIV drug resistance testing for patients with
confirmed VF should be considered.
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By the end of 2011, approximately 34 million people were
living with HIV globally, with almost all (97%) coming from
low and middle income countries (LMIC) [1]. In the same
year, more than 8 million HIV-infected individuals in LMIC
were receiving antiretroviral therapy (ART), up from just
400,000 in 2003 [2]. In Kenya, approximately 10,000 HIV-
infected individuals were on ART in 2003. By the end of
2011, more than 400,000 individuals had initiated ART in
the country [3]. The increase in the number of people with
access to ART has resulted in substantial declines in HIV
related incidence, morbidity and mortality [4-6]. However,
emerging HIV-drug resistance and subsequent treatment
failure threatens to reverse these gains. This is especially
important in sub-Saharan Africa (sSA) where the scale up
of ART has not always been done in tandem with the rele-
vant support for virological monitoring and HIVDR testing.
Regular virological monitoring has been shown to be
useful both in resource rich and resource limited settings
[7,8]. However, due to cost implications, this is not cur-
rently recommended for routine use in most developing
country settings. Instead, the World Health Organization
(WHO) recommend use of clinical and immunological
criteria to monitor treatment failure in resource limited
settings [9]. These criteria have been demonstrated to be
poor indicators of treatment failure, leading to missed op-
portunities or unnecessary medication switches [10-14],
which not only increase treatment costs, but also limit fu-
ture treatment options.
A systematic review of virological efficacy and drug re-
sistance outcomes of patients on ART programmes in sSA
has reported 76% virological suppression after 12 months
on ART and 67% after 24 months [15]. Similarly, a recent
systematic review from resource limited settings report
HIV drug resistance of 11% in patients on ART for 12–
23 months, 15% at 24–36 months and 21% at >36 months
[16]. The most common resistance profiles identified in-
clude the M184V mutation (associated with nucleoside re-
verse transcriptase inhibitors; NRTIs), followed by the
K103N mutation (associated with non-nucleoside reverse
transcriptase inhibitors; NNRTIs). Thymidine analogue mu-
tations (TAMs) and the K65R mutation were less common.
Emerging drug resistance and subsequent treatment fail-
ure poses a major concern for HIV programs in resource-
limited settings where treatment options are limited. This
study aimed to describe the prevalence and correlates of
HIV-1 virologic failure and acquired drug resistance
among first-line ART-experienced adults from a rural HIV
clinic in coastal Kenya.
Methods
Study site
The study was carried out at the HIV clinic in Kilifi
District Hospital; a rural public health facility located inCoastal Kenya. HIV services in the clinic are provided ac-
cording to the Kenyan national guidelines [17]. In brief,
immunological monitoring is recommended at enrolment
into care and six-monthly (or when clinically indicated)
thereafter. Individuals meeting the ART eligibility criteria
(WHO clinical staging III/IV regardless of CD4 T-cell
count or CD4 T-cell count of <350 cells/mm3 regardless
of clinical staging) undergo ART preparedness counseling
and are initiated on a standard first-line regimen.
At the time of the study, the national recommended
first-line therapy comprised two NRTIs (stavudine/zidovu-
dine and lamivudine) and one NNRTI (nevirapine/efavir-
enz). A gradual phase-out of stavudine as a first-line agent
was recommended in mid-2010. Adherence counseling
was done by nurse counselors. Individuals failing first-line
therapy were switched to an alternative combination of
two NRTIs and a boosted protease inhibitor (bPI) as the
recommended second line of choice.
At the time of the study, routine HIV-1 virologic moni-
toring and drug resistance testing were not recommended
in the Kenyan national guidelines. Targeted viral load
monitoring was introduced in 2011. A switch to the rec-
ommended second line regimen was recommended for in-
dividuals with virologic failure (persistent viral load ≥1000
copies/ml).
For this study, remnant blood from routine CD4 count
samples was centrifuged to obtain plasma, which was ar-
chived at −80 degrees centigrade and used for viral load
quantification and HIVDR testing.
Study design
An analytical cross-sectional study design was used. We
included HIV-infected adults (≥15 years old) who had
been on first-line ART for more than six months. Partic-
ipants with a previous history of ART exposure for pre-
vention of mother to child transmission (PMTCT) or for
post-exposure prophylaxis (PEP), and those on second
line regimens were excluded from the study.
Eligible participants were recruited in two phases. In the
first cross-section, all consenting eligible participants were
recruited between November 2008 and January 2009. At
the same time, a prospective cohort was established in
order to describe long-term outcomes of new clients en-
rolling for HIV care. All available plasma samples from
participants recruited in the prospective cohort and meet-
ing our eligibility criteria as at March 2011 were cross-
sectionally retrieved.
Sources of data
These have been previously described elsewhere [18]. In
brief, socio-demographic data including date of birth,
gender, marital status, level of education, religion and
sub-location of residence were routinely collected using
standardized questionnaires from all individuals at
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counselors. Actual distance to the clinic was estimated
from centroid co-ordinates of sub-locations in which
participants resided to the clinic using ArcInfo (Arc-
Catalog version 9.2, ESRI Corp).
Clinical data including anthropometry, opportunistic in-
fections, WHO staging, ART regimen, drug substitutions,
drug pick up dates and appointments were routinely col-
lected by trained clinicians on standardized forms at every
clinic encounter. Hematology and CD4 T-cell count data
were also collected. A trained data entry clerk entered
these data into an electronic data system.
Medicine Possession Ratio (MPR), defined as the
amount of time a participant is in possession of antire-
trovirals divided by the time between ARV drug pick-
ups, is increasingly being used as a proxy for assessing
adherence in retrospective analyses. We therefore retro-
spectively retrieved pharmacy drug refill data from 12
months (or from the date of ART initiation if follow up
period <12 months) prior to the date of sampling for
every individual participant. MPRs were calculated as
proportions of the total number of days between drug
pick-ups less the equivalent number of days in posses-
sion of ART divided by the time between drug pick-
ups for all visits. A mean MPR for each individual was
computed, subtracted from 100% and stratified to sa-
tisfactory (≥95%) and unsatisfactory (<95%) adherence
according to previously published conventions [19,20].Outcome definitions
The primary outcome was HIV-1 virologic failure (VF),
defined as a one-off HIV-1 plasma RNA viral load of ≥400
copies/ml. Viral load quantification was done using an in-
house assay. In brief, a multiplex real time quantitative
probe-based assay with an internal control and a series of
quantified HIV-1 standards was used to determine virus
concentration. The assay is designed to quantify HIV-1
plasma RNA for thresholds of 100 – 10,000,000 copies/ml.
The secondary outcome was acquired drug resistance
(ADR), determined by HIV-1 genotyping. Genotypic re-
sistance testing was done for all samples with VF using an
in-house assay which has been described elsewhere [21].
In brief, the assay amplifies and sequences part of the pol
sub-genomic region containing the protease and part of
the reverse transcriptase genes. Sequences were manually
edited and assembled against a reference sequence using
Sequencher software (GeneCodes, version 4.1). Sequences
were submitted to the Stanford HIV drug resistance
database to identify and interpret HIV-1 drug resistance
mutations [22,23].
Viral subtypes were identified by ‘Subtype Classification
Using Evolutionary Algorithm tool (SCUEAL)’ (http://
www.datamonkey.org/dataupload.php) [24].Sample size
A post-hoc sample size calculation was done to describe
whether the data would produce results with sufficient stat-
istical precision. This study assessed for HIV-1 VF among
232 patients on first-line antiretroviral therapy. Assuming a
HIV-1 VF prevalence of 24% after a median follow-up
period of 12 months on ART in our setting (based on 76%
virological suppression after 12 months on ARTas reported
in a systematic review elsewhere [15]), the risk of 232 ART
naïve adults started on first-line regimen and developing
VF over a median follow up period of twelve months could
be estimated with a precision of +/−6% at 95% confidence
level.
Data analysis
Continuous data are presented using medians (inter-
quartile ranges, IQR). Because of the relatively small
sample size, and except for marital status, all the expos-
ure variables were grouped into two categories. Continu-
ous data were stratified into two categories, using the
median as the guide to the stratification threshold. Fre-
quencies and column percentages were used to describe
categorical data.
The prevalence of HIV-1 VF was determined as a per-
centage of plasma samples with detectable viral load ≥400
copies/ml. The prevalence of ADR was determined as a
percentage of samples with detectable resistance asso-
ciated mutations (as identified by the Stanford HIV drug
resistance database) over the total number of samples with
VF that were successfully amplified and sequenced.
Univariable and multivariable logistic regression was
used to determine correlates of VF. Correlates with a like-
lihood ratio test (LRT) p-value of <0.05 from the univari-
able analysis were carried to the multivariable models
using the forward stepwise approach. Crude and adjusted
odd ratios (OR), 95% confidence intervals (CI) and LRT p-
values were presented. Because of the low frequency
observed, the Fishers exact test was used to assess for cor-
relates of ADR among all the participants included in the
study. Frequencies, row percentages and the Fisher’s exact
p-values were presented.
From a public health perspective, the Kenyan national
ART guidelines recommend use of persistent viral loads
of ≥1000 copies/ml as indicative of VF [25]. For com-
parison purposes with the study outcomes, this defi-
nition was also considered in the analyses, albeit from a
one-off sampling approach.
All analyses were carried out using STATA statistical soft-
ware (STATA Intercooled version 11, StataCorp, College
Station, Texas, USA).
Ethical considerations
The Kenya Medical Research Institute (KEMRI) Scientific
Steering Committee and the National ethics review
Table 1 Distribution of characteristics among first-line antiretroviral experienced adults on care at a rural HIV clinic in
coastal Kenya (N = 232)
Characteristic Categories Frequency [column %]
Cross-section 1 (n = 86) Cross-section 2 (n = 146) Total (n = 232)
Gender Male 16 [18.6] 38 [26.0] 54 [23.3]
Female 70 [81.4] 108 [74.0] 178 [76.7]
*Age (years) Median 36.5 39.3 38.5
[IQR] [31.4 – 44.4] [32.7 – 46.1] [32.2 – 44.8]
Age group (years) 15.0 – 34.9 33 [38.4] 47 [32.2] 80 [34.5]
≥ 35.0 53 [61.6] 99 [67.8] 152 [65.5]
Marital status Single 10 [11.6] 9 [6.2] 19 [8.2]
Married (monogamous/polygamous) 52 [60.5] 80 [54.8] 132 [56.9]
Separated/divorced/widowed 24 [27.9] 57 [39.0] 81 [34.9]
Religion Christian 64 [74.4] 88 [60.3] 152 [65.5]
Muslim 13 [15.1] 28 [19.2] 41 [17.7]
Others 9 [10.5] 30 [20.6] 39 [16.8]
Education status Primary schooling/less 68 [79.1] 119 [81.5] 187 [80.6]
Secondary/higher 18 [20.9] 27 [18.5] 45 [19.4]
*Distance (km) Median 7.8 7.8 7.8
[IQR] [2.2 – 21.0] [2.2 – 13.4] [2.2 – 15.7]
Group distance (km) < 10.0 50 [58.1] 98 [67.1] 148 [63.8]
≥ 10.0 36 [41.9] 48 [32.9] 84 [36.2]
Starting 1st line regimen Zidovudine based 37 [43.0] 81 [55.5] 118 [50.9]
Stavudine based 49 [57.0] 65 [44.5] 114 [49.1]
*Baseline WHO staging I/II 41 [47.7] 90 [61.6] 131 [56.5]
III/IV 44 [51.2] 56 [38.4] 100 [43.1]
Missing 1 [0.0] 0 [0.0] 1 [0.4]
*Baseline BMI (Kg/m2) Median 19.3 19.0 19.3
(IQR) [17.6 – 20.7] [17.3 – 21.1] [17.4 – 21.1]
Baseline BMI groups (Kg/m2) < 18.5 32 [37.2] 63 [43.2] 95 [41.0]
≥ 18.5 53 [61.6] 83 [56.9] 136 [58.6]
Missing 1 [1.2] 0 [0.0] 1 [0.4]
*Baseline CD4 count (cells/uL) Median 124 126 124
(IQR) [61 – 197] [35–193] [40–196]
Baseline CD4 groups (cells/uL) < 100 33 [38.4] 63 [43.2] 96 [41.4]
≥ 100 51 [59.3] 83 [56.9] 134 [57.8]
Missing 2 [2.3] 0 [0.0] 2 [0.9]
*Duration on ART (months) Median 13.3 15.0 13.9
[IQR] [9.0 – 16.1] [10.8 – 20.3] [10.0 – 18.3]
Group duration on ART (months) <12.0 32 [37.2] 49 [33.6] 81 [34.9]
≥ 12.0 54 [62.8] 97 [66.4] 151 [65.1]
Drug substitution No 68 [79.1] 100 [68.5] 168 [72.4]
Yes 18 [20.9] 46 [31.5] 64 [27.6]
WHO staging Stage I/II 54 [62.8] 78 [53.4] 132 [56.9]
Stage III/IV 32 [37.2] 68 [46.6] 100 [43.1]
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coastal Kenya (N = 232) (Continued)
*BMI (Kg/m2) Median 21.2 21.1 21.1
(IQR) [19.2 – 22.2] [19.4 – 24.5] [19.4 – 23.6]
BMI groups (Kg/m2) < 18.5 12 [14.0] 24 [16.4] 36 [15.5]
≥ 18.5 74 [86.1] 122 [83.6] 196 [84.5]
*CD4 count (cells/uL) Median 282 288 286
(IQR) [205–419] [193–387] [199–388]
CD4 groups (cells/uL) < 350.0 49 [57.0] 82 [56.2] 131 [56.5]
≥ 350.1 29 [33.7] 41 [28.1] 70 [30.2]
Missing 8 [9.3] 23 [15.8] 31 [13.4]
MPR adherence ≥ 95% (Satisfactory) 59 [68.6] 122 [83.6] 181 [78.0]
< 95% (Unsatisfactory) 24 [27.9] 19 [13.0] 43 [18.5]
Missing 3 [3.5] 5 [3.4] 8 [3.5]
Baseline refers to indicators at ART initiation; Follow up refers to indicators at the time of sampling; *Median [IQR, Inter-quartile ranges] for continuous variables;
BMI (Body Mass Index); WHO (World Health Organization); MPR (Medicine Possession Ratio); Zidovudine based (plus lamivudine/Nevirapine [n = 107] or
lamivudine/efavirenz [n = 11]); stavudine based (plus lamivudine/Nevirapine [n = 111] or lamivudine/efavirenz [n = 3]).
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Overall, 232 adults on first-line ART for a median du-
ration of 13.9 (IQR: 10.0 – 18.3) months were recruited.
The characteristics of participants recruited in the first
cross-section were not substantially different from those
recruited in the second cross-section (Table 1).
The majority of the participants were female (n = 178
[77%]), aged more than 35 years (n = 152 [66%]), married
(n = 132 [57%]), with a primary education or less (n = 187
[81%]) and living within 10 kilometers of the clinic (n = 148
[64%]) (Table 1). Half of the participants (n = 118) initiated
ART on a zidovudine-based regimen (plus lamivudine/nevi-
rapine, n = 107 [46%] or lamivudine/efavirenz, n = 11 [5%]);
the other half (n = 114) started on a stavudine-based regi-
men (plus lamivudine/nevirapine, n = 111 [48%] or lamivu-
dine/efavirenz, n = 3 [1%]). Over the follow up duration on
ART, 64 (28%) participants had undergone at least one drug
substitution and 43 (19%) had an average unsatisfactory
MPR adherence.
HIV-1 virologic failure
Of the 232 samples that underwent HIV-1 RNA viral load
quantification, 57 (24.6% [95% CI: 19.2 – 30.6]) demon-
strated VF. In univariable analysis, MPR adherence, age
group and marital status were significantly correlated with
VF. In multivariable analysis, only MPR adherence and age
group remained independently associated withVF (Table 2).
Participants with an average unsatisfactory MPR adherence
had three-fold odds of having VF, compared to those withan average satisfactory MPR adherence (aOR [95% CI],
p-value: 3.0 [1.5 – 6.5], p = 0.003). Likewise, participants
aged ≥35 years had 70% lower odds of having VF, compared
to those aged 15 – 34 years old (0.3 [0.1 – 0.6], p < 0.001).
Adjusting for age attenuated the effect of marital status
on VF towards the null (Separated/divorced/widowed vs.
single, 0.4 [0.1 – 1.2], p = 0.137).
HIV-1 acquired drug resistance
Fifty-five of the 57 samples with VF were successfully amp-
lified and sequenced for HIV drug resistance testing. Of the
55 samples that were successfully amplified and sequenced,
29 (52.7% [95% CI: 38.8 – 66.3]) had at least one detectable
HIV-1 resistance associated mutation, giving an overall
ADR prevalence of 12.5% (95% CI: 8.5 – 17.5) among all
participants included in the study. While all 29 samples had
mutations conferring resistance to NNRTIs, 25 (86%) of
those with resistance had dual-class (both NRTIs and
NNRTIs) mutations (Table 3). The most prevalent variant
were the M184V mutation (n = 24), the K103N/S mutation
(n = 14) and the Y181C/Y/I/V mutation (n = 8) within the
reverse transcriptase genome. Thymidine analogue muta-
tions (TAMs) were present in 4 participants. Twenty-six of
the 55 successfully amplified viraemic samples (47.3%) did
not have any detectable resistance associated mutations.
Viral load, MPR adherence and age group were
strongly associated with ADR (Table 4). Participants
with higher viral loads (≥ 4.0 log copies/ml) had a higher
prevalence of ADR, compared to those with lower viral
loads (< 4.0 log copies/ml), (frequency [%]: 20 [62.5] vs 9
[4.6], p < 0.001). Likewise, participants with unsatisfac-
tory MPR adherence had a higher prevalence of ADR,
compared to those with satisfactory MPR adherence
(frequency [%]: 12 [27.9] vs 17 [9.5], p = 0.004). Similarly,
Table 2 Logistic regression analysis describing correlates of HIV-1 virologic failure (viral load ≥400 copies/ml) among st-line antiretroviral experienced adults




analysis (n = 201)
Risk factors Categories Viraemia, n = 57 [%] Crude OR 95% C.I *P-val Adjusted OR 95% C. I *P-value
Gender Male 12/54 [22.2] 1.0
Female 45/177 [25.3] 1.2 0.6 – 2.4 0.645 - - -
Age group (years) 15.0 – 34.9 31/80 [38.8] 1.0 1.0
≥ 35.0 26/152 [17.1] 0.3 0.2 – 0.6 <0.001 0.3 0.2 – 0.7 0.002
Marital status Single 8/19 [42.1] 1.0
Married (monogamous/polygamous) 36/132 [27.3] 0.5 0.2 – 1.4
Separated/Divorced/Widowed 13/81 [16.1] 0.3 0.1 – 0.8 0.034 - - -
Religion Christian 38/152 [25.0] 1.0
Muslim 7/41 [17.1] 0.6 0.3 – 1.5
Others 12/39 [30.8] 1.3 0.6 – 2.9 0.345 - - -
Education status Primary schooling/Less 46/187 [24.6] 1.0
Secondary/Higher 11/45 [24.4] 1.0 0.5 – 2.1 0.983 - - -
Group distance (km) <10.0 37/148 [25.0] 1.0
≥ 10.0 20/84 [23.8] 0.9 0.5 – 1.8 0.839 - - -
Starting 1st line regimen Zidovudine based 33/118 [28.0] 1.0
Stavudine based 24/114 [21.1] 0.7 0.4 – 1.3 0.221 - - -
Baseline WHO staging I/II 28/131 [21.4] 1.0
III/IV 28/100 [28.0] 1. 4 0.8 – 2.6 0.246 - - -
Baseline BMI groups (Kg/m2) < 18.5 26/95 [27.4] 1.0
≥ 18.5 30/136 [22.1] 0.8 0.4 – 1.4 0.356 - - -
Baseline CD4 groups (cells/uL) < 100 25/96 [26.0] 1.0
≥ 100 30/134 [22.4] 0.8 0.4 – 1.5 0.523 - - -
Duration on ART (months) <12.0 23/81 [28.4] 1.0
≥ 12.0 34/151 [22.5] 0.7 0.4 - 1.4 0.325 - - -
Drug substitution No 40/168 [23.8] 1.0
Yes 17/64 [26.6] 1.2 0.6 – 2.2 0.665 - - -
Follow up WHO staging Stage I/II 29/132 [22.0] 1.0
Stage III/IV 28/100 [28.0] 1.4 0.8 – 2.5 0.292 - - -
Follow up BMI groups (Kg/m2) < 18.5 10/36 [27.8] 1.0





















Table 2 Logistic regression analysis describing correlates of HIV-1 virologic failure (viral load ≥400 copies/ml) among first-line antiretroviral experienced adults
at a rural HIV clinic in coastal Kenya (N = 232) (Continued)
Follow up CD4 groups (cells/uL) < 350 35/131 [26.7] 1.0
≥ 350 12/70 [17.1] 0.6 0.3 – 1.2 0.120 - - -
MPR adherence ≥ 95% (Satisfactory) 34/181 [18.8] 1.0 1.0
<95% (Unsatisfactory) 18/43 [41.9] 3.1 1.5 – 6.3 0.002 3.0 1.5 – 6.5 0.003
Baseline refers to indicators at ART initiation; Follow up refers to indicators at the time of sampling; *Likelihood Ratio Test p-value; BMI (Body Mass Index); WHO (World Health Organization); MPR (Medicine Possession




















Table 3 Distribution and characteristics of first-line antiretroviral experienced adults with HIV-1 acquired drug
resistance mutations from a rural HIV clinic in coastal Kenya
No. Gender Age (years) Sample date ART date ART duration# Viral load Subtype* NRTI mutations NNRTI mutations
1. Male 30.5 28-Nov-08 28-Mar-08 8.0 697796 Complex D67DG K103N, G190A
2. Female 38.5 02-Dec-08 22-May-08 6.4 5006 A1 M184V K103N, K238T
3. Male 36.6 06-Jan-09 11-Apr-08 8.9 861730 A1 M184V Y188L
4. Female 33.4 17-Nov-08 19-May-08 6.0 64435 A1 M184V, K219EK V108IV, Y181CY,
G190AG
5. Female 44.5 16-Dec-08 26-Nov-07 12.7 3087 A1 M184V G190A
6. Female 26.5 17-Dec-08 01-Nov-07 13.5 1158 D M184V K103N, K238T
7. Female 22.5 05-Dec-08 30-Oct-07 13.2 4051 A1 M184V K103N
8. Female 48.4 12-Nov-08 02-Jul-07 16.4 5274 A1 M184V K103N, M230LM
9. Female 24.4 12-Nov-08 29-Aug-07 14.5 24529 D T69NT, M184V K103N
10. Female 63.4 21-Nov-08 03-May-07 18.7 576 A1, AE K103N
11. Female 25.6 14-Jan-09 22-Oct-07 14.8 219766 A-ancestral, A1 M184V, T215Y Y181C
12. Female 31.3 07-Oct-10 22-Aug-08 25.5 315800 A1 M184V K103N
13. Female 34.0 22-Jun-10 07-Oct-09 8.5 17248 A1 M184V Y181C
14. Female 25.2 13-Sep-10 19-Aug-09 12.8 109090 D M184V V106A, F227L
15. Female 51.2 10-Aug-10 15-Jun-09 13.8 5396 A1 M184V K103N
16. Female 23.7 08-Mar-11 22-Sep-09 17.5 12408 A1 M184V Y181C
17. Female 32.1 06-Jul-10 15-Dec-08 18.7 199362 A1 M41L, D67N, K70R,
M184V, T215Y, K219Q
Y181IV
18. Female 31.8 23-Mar-11 27-Feb-09 24.8 834656 A-ancestral, A1 K101E, G190A
19. Female 38.7 16-Feb-10 22-May-09 8.9 34186 A2 M184V V106A
20. Female 41.8 20-Apr-10 22-Jun-09 9.9 4729 A1 M184V Y181C
21. Female 31.7 04-Mar-11 24-Mar-09 23.3 20392 A1 M184V V106A
22. Female 15.1 16-Mar-10 13-Apr-09 11.1 1046760 A1 M184V K103S, G190A
23. Female 31.3 29-Sep-10 11-Jan-10 8.6 129493 A1, A2 K103N
24. Female 41.7 11-Mar-11 18-Aug-09 18.7 1452 A, A1 M184V Y181C
25. Female 17.8 07-Mar-11 08-Dec-09 14.9 130222 A1 M184V K103N, Y318FY
26. Female 25.7 04-Mar-11 13-Apr-10 10.7 47795 A1 M184V K101Q, G190A
27. Female 21.7 11-Mar-11 01-Sep-09 18.3 2029880 A1 L74V, M184V K103N, Y181C
28. Female 48.1 02-Aug-10 08-Oct-08 21.8 72430 A1 G190A
29. Male 29.5 14-Dec-10 06-Jan-10 11.2 74152 A, A1 K65R, M184V K103N
#Time (in months) since patient started taking antiretroviral therapy, *HIV-1 subtypes identified using the ‘Subtype Classification Using Evolutionary ALgorithm
(SCUEAL)’ tool, available at (www.datamonkey.org/dataupload_scueal.php).
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ADR compared to those aged ≥35 years (frequency [%]:
19 [23.8] vs 10 [6.7], p < 0.001).
Age was further stratified to 10-year age bands and its as-
sociation withVF and ADR explored. The overall prevalence
of VF and ADR was highest in participants aged 15–24 years
(53.3% and 40.0% respectively) (Figure 1). Strong evidence
of a decreasing trend in prevalence of VF and ADR with in-
creasing age groups (non-parametric test for trend, p =
0.004 and p < 0.001 respectively) was also observed.
For comparison purposes, the above analyses were re-
peated using viral load threshold of ≥1000 copies/ml to
define VF. Of the 232 participants, 48 (20.7% [95% CI:
15.7 – 26.5]) met this criterion of HIV-1 VF. Of these, 28
(58.3% [95% CI: 43.2 – 72.4]) had at least one detectableHIV-1 resistance mutation. Correlates of VF (Additional
file 1: Table S1) and ADR (Additional file 1: Table S2)
remained the same as those observed when using this
study’s outcome definition of ≥400 copies/ml for VF.
Discussion
Findings from a HIV clinic in a rural district hospital in
coastal Kenya suggest that one in every four adults on
first-line antiretroviral regimen for an average of 14
months had VF, with half of those with VF harboring at
least one HIV resistance-associated mutation. The most
prevalent mutations observed confer high-level resistance
to NRTIs (specifically lamivudine, in the case of the
M184V mutation) and NNRTIs (specifically nevirapine
and efavirenz, in the case of the K103N/S mutation and
Table 4 Distribution and correlates of HIV-1 acquired drug resistance among first-line antiretroviral experienced adults
at a rural HIV clinic in coastal Kenya (N = 230)
Acquired drug resistance [row %]
Risk factors Categories No (n = 201) Yes (n = 29) *P-value
Gender Male 51 [94.4] 3 [5.6]
Female 150 [85.2] 26 [14.8] 0.100
Age group (years) 15.0 – 34.9 61 [76.3] 19 [23.8]
≥ 35.0 140 [93.3] 10 [6.7] <0.001
Marital status Single 13 [68.4] 6 [31.6
Married (monogamous/polygamous) 113 [86.3] 18 [13.7]
Separated/divorced/widowed 75 [93.8] 5 [6.3] 0.013
Religion Christian 132 [87.4] 19 [12.6]
Muslim 36 [87.8] 5 [12.2]
Others 33 [86.8] 5 [13.2] 1.000
Education status Primary schooling/less 162 [87.6] 23 [12.4]
Secondary/higher 39 [86.7] 6 [13.3] 0.807
Group distance (km) <10.0 128 [86.5] 20 [13.5]
≥10.0 73 [89.0] 9 [11.0] 0.681
Starting 1st line regimen Zidovudine based 102 [86.4] 16 [13.6]
Stavudine based 99 [88.4] 13 [11.6] 0.695
Baseline WHO staging I/II 117 [90.0] 13 [10.0]
III/IV 83 [83.8] 16 [16.2] 0.228
Baseline BMI groups (Kg/m2) < 18.5 82 [88.2] 11 [11.8]
≥ 18.5 118 [86.8] 18 [13.2] 0.841
Baseline CD4 groups (cells/uL) <100 82 [86.3] 13 [13.7]
> 100 118 [88.7] 15 [11.3] 0.683
Duration on ART (months) < 12.0 70 [86.4] 11 [13.6]
≥ 12.0 131 [87.9] 18 [12.1] 0.836
Drug substitution No 145 [87.4] 21 [12.7]
Yes 56 [87.5] 8 [12.5] 1.000
Follow up WHO staging Stage I/II 119 [91.5] 11 [8.5]
Stage III/IV 82 [82.0] 18 [18.0] 0.044
Follow up BMI groups (Kg/m2) < 18.5 30 [83.3] 6 [16.7]
≥ 18.5 171 [88.1] 23 [11.9] 0.417
Follow up CD4 groups (cells/uL) < 350 110 [84.6] 20 [15.4]
≥ 350 64 [91.4] 6 [8.6] 0.193
MPR adherence ≥ 95% (Satisfactory) 162 [90.5] 17 [9.5]
< 95% (Unsatisfactory) 31 [72.1] 12 [27.9] 0.004
Viral load (log 10, copies/ml) 0.00 – 4.00 189 [95.5] 9 [4.6]
> 4.00 12 [37.5] 20 [62.5] <0.001
Baseline refers to indicators at ART initiation; Follow up refers to indicators at the time of sampling; *Fisher’s exact p-value; BMI (Body Mass Index); WHO
(World Health Organization) MPR (Medicine Possession Ratio). Missing data; Baseline WHO staging (n = 1 [0.4%]), Baseline BMI (n = 1 [0.4%]), Baseline CD4 count
(n = 2 [0.9%]), CD4 count (n = 31 [13.4%]) and MPR adherence (n = 8 [3.5%]).
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with findings from systematic reviews of studies on viro-
logical efficacy and drug resistance from other resource
limited settings [15,26]. The non-complex resistance pat-
terns observed could possibly indicate an advantage of the
current recommended first-line regimen in this setting.The WHO recommends use of drug-refill data as an early
warning indicator (EWI) of HIV treatment failure and drug
resistance [27]. Recent EWI analyses on prospective
HIVDR data from 6 African countries suggest an advantage
of MPR over on-time drug pick-up in identifying partici-
pants at risk for developing HIV drug resistance [28]. For
Figure 1 Overall prevalence and distribution of HIV-1 Viraemia (viral load ≥400 copies/ml) and acquired drug resistance by age group,
among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya (N=232).
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tical alternative parameter for assessing adherence, with
strong correlation with both VF and ADR in this setting.
Similar findings have also been reported elsewhere
[19,29-31].
The current study also indicated younger age as a strong
risk factor for both HIV-1 VF and ADR. In fact, half of all
participants aged 15–24 years had VF, while two in every
five had acquired at least one drug resistant strain. Data
from a developed setting suggests that the youth face a
complex myriad of challenges including peer-related
stigma, disclosure, adherence, sexual, reproductive and
gender health concerns [32]. If applicable, then these chal-
lenges may indirectly contribute to the high burden of
virological treatment failure and ADR in our setting.
Higher viral load was strongly associated with ADR,
which is consistent with literature [33]. Of interest how-
ever, is the finding that only half of participants with VF
had detectable ADR. Indeed, if the Kenyan national rec-
ommendation of ≥1000 copies/ml was used to suggest VF
in this study [25], and assuming sustained viral replication,
then a fifth of the participants would have VF. Of these,
only 58% had detectable ADR mutations. These data may
therefore suggest that up to 42% of participants would
have potentially been switched to the more expensive 2nd
line regimen prematurely or unnecessarily, thus exhaust-
ing and limiting treatment options. This is especially risky
in this setting where the only currently recommended sec-
ond line option is the bPIs, with costs prohibiting the
range of other potential alternative regimens.
The findings of this study should be interpreted in
light of several limitations. Firstly, the cross-sectionalstudy design and the one-off sampling strategy warrant
caution in the interpretation of our findings, as follow up
samples were not available to confirm VF. Consequently,
blips in viral load cannot be ruled out [34]. It is acknowl-
edged that occasionally, viral blips can occur even during
effective treatment [35,36]. This may have resulted to an
overestimation of the true burden of VF in this population.
In addition, focusing on participants with a median ART
follow up duration of more than a year potentially ex-
cludes those who may have died or were lost to follow-up
within a year of ART due to treatment failure. This may
have resulted in an underestimation of the true burden of
VF and ADR in this population.
Secondly, it may be argued that the participants may not
have achieved virological suppression in the first place, even
after being on ART for more than 6 months. This may pos-
sibly be attributed to the effect of persisting HIV-1 primary
or transmitted resistance mutations, which have been re-
ported to be on the increase in some parts of sSA [37,38].
Transmitted resistant strains have been shown to contrib-
ute to VF in clients on ART [39-41]. However, our concur-
rent data suggest low levels (<5%) of transmitted drug
resistance in this rural coastal Kenyan population [42].
Lastly, stigma, disclosure, sexual orientation, reproductive
health and gender issues are potential concerns that may
contribute to the burden of VF and ADR, especially among
the young adults in this setting. Data on these factors were
not captured and hence not considered in the analyses.
Conclusions
In conclusion, levels of HIV-1 VF and ADR observed from
this rural HIV clinic in coastal Kenya were comparable to
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levels of VF and ADR were observed among younger pa-
tients and those with unsatisfactory adherence. Implementa-
tion of youth-friendly ART initiatives (e.g. social networks,
support clubs) are therefore warranted in this setting.
Strengthened adherence support should also be prioritized,
more so in cases of suspected virologic treatment failure
and before treatment switches. However, if virologic failure
is confirmed, targeted HIVDR testing should be considered
to prevent unnecessary/premature switches.
Additional file
Additional file 1: Table S1. Logistic regression analysis describing
correlates of HIV-1 virologic failure (viral load ≥1000 copies/ml) among
first line antiretroviral experienced adults at a rural HIV clinic in coastal
Kenya (N=232). Table S2. Distribution and correlates of HIV-1 acquired
drug resistance (if genotyping was only done for samples with viral
load ≥1000 copies/ml) among first-line antiretroviral experienced adults
at a rural HIV clinic in coastal Kenya (N=230).
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